A Controlled Trial of Bupropion Added to Nicotine Patch and Behavioral Therapy for Smoking Cessation in Adults with Unipolar Depressive Disorders

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms, achieving smoking abstinence was associated with a significantly higher rate of worsening depressiv

Effect: decline; 56% (35/63) vs 27% (6/22), Chi2=4.60, p=0.032

Bupropion was not protective against abstinence-associated increases in depressive symptoms among smokers with unipolar depressive disorders who entered the trial with low depressive symptoms and achi

Effect: null; 50% (17/34) vs 62% (18/29), Chi2=0.923, p=0.34

Comorbid lifetime anxiety disorder was associated with significantly lower smoking abstinence rates at end of treatment compared to no anxiety disorder, among smokers with unipolar depressive disorder

Effect: decline; 23% (18/79) vs 41% (49/120), Chi2=6.9, p<0.01

Greater adherence to transdermal nicotine patch use was significantly associated with higher odds of achieving smoking abstinence at end of treatment.

Effect: improvement; OR 1.06 per patch used; CI: 95% CI: 1.03-1.08